WEBULL
WebtradeDownload

Analysts Expect Breakeven For Nanobiotix S.A. (EPA:NANO) Before Long

Simply Wall St · 2d ago

We feel now is a pretty good time to analyse Nanobiotix S.A.'s (EPA:NANO) business as it appears the company may be on the cusp of a considerable accomplishment. Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. On 31 December 2025, the €1.6b market-cap company posted a loss of €24m for its most recent financial year. Many investors are wondering about the rate at which Nanobiotix will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Consensus from 7 of the French Biotechs analysts is that Nanobiotix is on the verge of breakeven. They expect the company to post a final loss in 2027, before turning a profit of €33m in 2028. So, the company is predicted to breakeven approximately 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 56% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
ENXTPA:NANO Earnings Per Share Growth September 11th 2026

We're not going to go through company-specific developments for Nanobiotix given that this is a high-level summary, however, take into account that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for Nanobiotix

One thing we would like to bring into light with Nanobiotix is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. Oftentimes, losses exist only on paper but other times, it can be a red flag.

Next Steps:

There are too many aspects of Nanobiotix to cover in one brief article, but the key fundamentals for the company can all be found in one place – Nanobiotix's company page on Simply Wall St. We've also compiled a list of essential aspects you should look at:

  1. Valuation: What is Nanobiotix worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Nanobiotix is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Nanobiotix’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.